Heartland Advisors Inc. Reduces Stock Position in Haemonetics Co. (NYSE:HAE)

Heartland Advisors Inc. trimmed its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 34.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,923 shares of the medical instruments supplier's stock after selling 48,175 shares during the quarter. Heartland Advisors Inc. owned about 0.19% of Haemonetics worth $7,255,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in shares of Haemonetics by 174.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier's stock worth $1,362,000 after acquiring an additional 10,774 shares during the last quarter. Boston Trust Walden Corp boosted its holdings in Haemonetics by 13.1% in the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock valued at $71,500,000 after purchasing an additional 106,114 shares during the last quarter. FMR LLC grew its stake in shares of Haemonetics by 206.3% in the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier's stock valued at $62,257,000 after buying an additional 521,640 shares during the period. Empowered Funds LLC purchased a new stake in shares of Haemonetics in the 4th quarter valued at approximately $319,000. Finally, Pacer Advisors Inc. raised its position in shares of Haemonetics by 36.1% during the 4th quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock valued at $789,000 after buying an additional 2,680 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

Remove Ads

Haemonetics Stock Up 1.0 %

Haemonetics stock traded up $0.66 during mid-day trading on Wednesday, reaching $63.68. 103,198 shares of the company's stock were exchanged, compared to its average volume of 664,875. The company has a fifty day moving average of $65.60 and a 200-day moving average of $74.54. The company has a market cap of $3.20 billion, a P/E ratio of 25.07, a P/E/G ratio of 1.11 and a beta of 0.43. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a twelve month low of $58.80 and a twelve month high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Sell-side analysts expect that Haemonetics Co. will post 4.55 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Raymond James reiterated a "strong-buy" rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price target for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Needham & Company LLC decreased their target price on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Finally, Barrington Research decreased their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.